Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. Price to Earnings Ratio (P/E) on February 05, 2025: -1.05

Biomea Fusion, Inc. Price to Earnings Ratio (P/E) is -1.05 on February 05, 2025, a 81.65% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Biomea Fusion, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.94 on January 03, 2025, which is 10.34% above the current Price to Earnings Ratio (P/E).
Biomea Fusion, Inc. 52-week low Price to Earnings Ratio (P/E) is -5.78 on February 27, 2024, which is -452.42% below the current Price to Earnings Ratio (P/E).
Biomea Fusion, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.51.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years